跳转至内容
Merck

1625009

USP

磺胺嘧啶

United States Pharmacopeia (USP) Reference Standard

别名:

N-2-嘧啶基-4-氨基苯磺酰胺, N1-(嘧啶-2-基)磺胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C10H10N4O2S
CAS号:
分子量:
250.28
Beilstein:
6733588
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

sulfadiazine

製造商/商標名

USP

mp

253 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

InChI 密鑰

SEEPANYCNGTZFQ-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Sulfadiazine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Silver Sulfadiazine Cream
  • Sulfadiazine
  • Sulfadiazine Sodium
  • Sulfadiazine Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

K Becker et al.
Medicine, 75(4), 185-194 (1996-07-01)
We performed a computerized search on sulfadiazine-associated nephrotoxicity reported in human immunodefiency virus (HIV)-infected patients in the international literature. Including an original case report, we summarized 35 acquired immunodefiency syndrome (AIDS) patients from 1987 to 1995 in an analysis comparing
U Kronawitter et al.
Deutsche medizinische Wochenschrift (1946), 118(46), 1683-1686 (1993-11-19)
A 45-year-old man with AIDS was treated for a recurrence of cerebral toxoplasmosis with sulphadiazine, 4 g, and pyrimethamine, 75 mg, daily. Owing to a lack of appetite and dysphagia he drank rather little water during the first week of
Charlotte Catalano-Pons et al.
Pediatric nephrology (Berlin, Germany), 19(8), 928-931 (2004-06-19)
Sulfadiazine-associated urinary calculi have been described in HIV-positive adult patients but rarely in children. We report two pediatric cases of sulfadiazine-induced nephrolithiasis and review 45 adult cases from the literature. One had a hyper-IgM syndrome and was treated with sulfadiazine
D I Simon et al.
Archives of internal medicine, 150(11), 2379-2384 (1990-11-01)
Toxoplasma gondii encephalitis is an important opportunistic infection in the acquired immunodeficiency syndrome, estimated to occur in 20,000 to 40,000 patients with acquired immunodeficiency syndrome in the United States by 1991. The combination of sulfadiazine and pyrimethamine is regarded as
S Hoffmann
Scandinavian journal of plastic and reconstructive surgery, 18(1), 119-126 (1984-01-01)
Topical antibacterial treatment is of major importance in the burn patient. Silver sulfadiazine is an effective agent with low toxicity and few side effects. Deposition of silver in tissues, and absorption of sulfadiazine are both minimal. Present and future problems

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门